Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michael McCaughan

Michael McCaughan has has 25 years of experience providing analysis and insight about the biopharma industry, including 10 years as Editor-In-Chief of The Pink Sheet and The Pink Sheet DAILY. He speaks frequently on regulatory and policy developments affecting the industry.

Latest From Michael McCaughan

Drug Pricing Day At The US Supreme Court

Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.

Pricing Debate Legal Issues

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA commissioner Janet Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

FDA Leadership

What Might Have Been: US FDA Acting Commissioner Woodcock Testifies In Senate

Acting FDA Commissioner Woodcock’s latest appearance before Senate Health Committee shows once again she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

FDA Leadership

What Might Have Been: US FDA’s Woodcock Testifies In Senate

Acting US FDA Commissioner Woodcock’s latest appearance before the Senate Health Committee shows once again that she could easily win enough votes for Senate confirmation in the job – and why she most likely won’t get the chance.

FDA Leadership

The End Of Small Molecule Drugs? Potential Implications Of US Price ‘Negotiation’

The drug pricing provisions in the Build Back Better bill include a number of exemptions and protections – each of which could have interesting consequences for pharmaceutical development.

Pricing Debate Reimbursement

Aduhelm And The Power Of Doubt

CMS is famous for not being able to negotiate prices – and its payment for physician-administered drugs notoriously incentivizes higher prices. Yet, as the Biogen/Eisai Aduhelm experience shows, CMS can on occasion have a profound impact on product launches when it chooses to.

Medicare Reimbursement
See All
UsernamePublicRestriction

Register